Merck & Co. Inc. (MRK)
Health Care11 articles
Price chart
Merck & Co. Inc. (MRK) overview
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Merck & Co. Inc. trades on the NYSE under the ticker symbol MRK. As of the most recent market data, the stock was priced around $149.71, up 1.32% on the session, giving Merck & Co. Inc. a market capitalization of roughly $369.36B.
Over the past 52 weeks, MRK has traded between $77.58 and $156.92. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 120.7, a common gauge of how richly the market prices the company's earnings. Merck & Co. Inc. also pays a dividend, currently yielding around 2.29%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MRK
As one of the larger companies in the Health Care sector, Merck & Co. Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch MRK for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Merck & Co. Inc.'s size means its share-price moves can also nudge the index as a whole, making MRK a stock that even index investors pay attention to.
Market Mood
Latest MRK news
Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) and Merck (MRK) have reported a breakthrough in developing a cancer vaccine aimed at preventing melanoma recurrence. This is a significant event, marking progress after a century of unsuccessful attempts in cancer vaccine research. The announcement highlights the collaboration between the two companies, potentially impacting their stock performance and investor interest. Investors may want to monitor the developments closely, as advancements in cancer treatment can influence market dynamics and investment strategies in the healthcare sector.
Read More: Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.
Read More: Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Merck EVP DeLuca sells $5.9M in stock transaction
Merck's (MRK) Executive Vice President, DeLuca, has sold $5.9 million worth of stock. This sale comes as part of a routine exercise of stock options. The transaction is significant as insider selling can sometimes indicate a lack of confidence in the company’s future performance. For investors, such sales can suggest potential caution regarding the stock's short-term outlook, making it important to monitor insider activity.
Read More: Merck EVP DeLuca sells $5.9M in stock transaction
Merck (MRK) Q2 2026 Results Show Revenue Growth Despite Profit Cut
Merck & Co., Inc. (MRK) reported its second-quarter 2026 financial results, noting increased revenue driven by new drug sales. The company raised its revenue outlook, but also reduced its profit guidance due to charges related to deals. Keytruda significantly contributed to the positive performance, leading to better-than-expected results. This revenue growth combined with the outlook adjustments is important for investors, as it indicates how Merck is navigating financial challenges while capitalizing on new products.
Read More: Merck (MRK) Q2 2026 Results Show Revenue Growth Despite Profit Cut
Stocks Pre-Market Moves: McDonald's, Caterpillar, Palantir Insights
Several companies are making notable pre-market moves including McDonald's, Caterpillar, Palantir, and Merck. Each stock's movements can be indicative of market trends and investor sentiment, potentially impacting trading volumes significantly. Investors should monitor these changes as they may affect overall market direction and individual stock performance. This information is crucial for ordinary investors looking to make informed decisions based on market movements.
Read More: Stocks Pre-Market Moves: McDonald's, Caterpillar, Palantir Insights
Merck (MRK) Earnings Outlook: New Launches and Margin Squeeze
Merck (MRK) is preparing for its upcoming earnings report, with expectations on whether new product launches can compensate for declining margins. Analysts are keenly observing how these launches will impact overall profitability. The company faces challenges from a margin squeeze, which requires substantial performance from its new offerings to maintain competitiveness. This earnings report will inform investors whether Merck's strategy is viable moving forward, making it relevant for those interested in the pharmaceutical sector.
Read More: Merck (MRK) Earnings Outlook: New Launches and Margin Squeeze
Merck's (MRK) Cholesterol Pill Lipfendra Gains FDA Approval
Merck (MRK) announced that the U.S. FDA approved Lipfendra, the first oral PCSK9 inhibitor for treating hypercholesterolemia. This approval comes as Merck's Keytruda faces patent expirations in 2028, which could lead to competition from biosimilars. Lipfendra's approval was based on late-stage trials demonstrating significant reductions in LDL cholesterol levels. Analysts suggest Lipfendra could have peak sales potential worth tens of billions of dollars. This matters for investors as Lipfendra diversifies Merck's offerings beyond oncology, potentially stabilizing revenue streams.
Read More: Merck's (MRK) Cholesterol Pill Lipfendra Gains FDA Approval
Merck (MRK) Stock Price Target Raised to $145 by Guggenheim
Guggenheim has increased its price target for Merck (MRK) to $145, citing a favorable outlook for the company's pipeline. This reassessment reflects confidence in Merck's future product offerings, potentially influencing investor sentiment. The updated price target may impact trading volumes and market activity for Merck shares. For ordinary investors, this adjustment suggests a bullish outlook on Merck's stock performance moving forward.
Read More: Merck (MRK) Stock Price Target Raised to $145 by Guggenheim
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More: BMY vs JNJ: Healthcare Revenue Comparison for 2025
Merck's (MRK) pembrolizumab Receives Orphan Drug Status from FDA
Merck's (MRK) pembrolizumab has been granted orphan drug status by the FDA for treatment in neuroendocrine prostate cancer (NEPC). This designation is significant as it provides benefits such as market exclusivity and potential financial incentives for research and development. The orphan drug status can enhance Merck's positioning in the oncology market, potentially leading to increased sales once approved. The market impact could be positive as investors may view this as a step towards expanding Merck's product offerings in a niche area of cancer treatment.
Read More: Merck's (MRK) pembrolizumab Receives Orphan Drug Status from FDA
Merck (MRK), IMAX, Estee Lauder Stocks Showing Premarket Movements
In premarket trading, notable stocks include Merck (MRK), IMAX, and Estee Lauder. Specific price movements and percentage changes were not detailed in this report. Such fluctuations can indicate market sentiment and investor reactions to events or reports influencing these companies. Market participants should monitor these stocks closely as premarket movements can impact openings and trading volumes when the market opens.
Read More: Merck (MRK), IMAX, Estee Lauder Stocks Showing Premarket MovementsMore Health Care stocks
Frequently asked questions
Is Merck & Co. Inc. in the S&P 500?
Yes. Merck & Co. Inc. (MRK) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is MRK in?
Merck & Co. Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest MRK news?
This page collects recent Merck & Co. Inc. (MRK) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Merck & Co. Inc.'s stock price?
As of the most recent market data, Merck & Co. Inc. (MRK) traded at approximately $149.71. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Merck & Co. Inc.'s market cap?
Merck & Co. Inc. has a market capitalization of roughly $369.36B, based on its most recent share price and shares outstanding.
What is MRK's P/E ratio?
MRK trades at a trailing price-to-earnings ratio of about 120.7. The P/E ratio compares a company's share price to its earnings per share.